INTRODUCTION
============

*Panax ginseng* has been used as an herbal medicine for more than 2000 years in the Orient [@B001]. About 200 constituents from *P. ginseng* have been isolated and characterized [@B002],[@B003]. Its major components are ginseng saponins and polysaccharides. The major pharmacological effect of ginseng is adaptogenic effect. In other words, ginseng nonspecifically increases resistance to various hazardous stimuli of physical, chemical, and biological stress through immunomodulation and hyphothalmic-pituitaryadrenal axis [@B004],[@B005]. Recent literatures show the potential of adjuvant or as immunotherapeutics of ginseng [@B006]-[@B014].

Although there have been many reports on the association between genetic defects and clinical courses in HIV- 1 infected patients [@B015]-[@B022], gross deletion in the *nef* gene (Δ*nef*) has been reported in very limited proportion even in elite controllers [@B023]. We previously reported that Korean red ginseng (KRG) increases the frequency of gΔ*nef* and gross deletion in 5'LTR/*gag* regions as well as slow progression in HIV-1 infected individuals [@B024]-[@B028]. Thus, we could obtain several long-term survivors for more than 20 years in the absence of antiretroviral therapy among our ginseng cohort [@B024],[@B027]. In Korea, the longest survivor among HIV-1 infected patients was diagnosed in 1987 and in the absence of highly active antiretroviral therapy (HAART) has maintained his CD4 T cell count since 1994. They all reveal genetic defects in the Δ*nef* or 5'LTR/*gag* although the proportion of defected amplicons was less than 20% and 50%, respectively [@B027]. In addition, we reported that HAART significantly decreases the frequency of gΔ*nef* caused by KRG intake in 20 hemophiliacs who were infected with Korean subclade B of HIV-1 [@B026]. In this study, we investigated whether KRG and HAART affect the frequency of gross deletion in 5'LTR/*gag* in 20 hemophiliacs.

MATERIALS AND METHODS
=====================

Study subjects
--------------

This study consisted of 20 hemophiliac patients (HPs) infected with Korean subclade of HIV-1 subtype B (KSB) [@B026],[@B029]. All patients were infected with HIV-1 in between late 1989 and April 1991. The time on the first use of domestic clotting factor was described in [Table 1](#T001){ref-type="table"} in the reference 29. Age at HIV-1 diagnosis was from 4 to 39 years. Informed written consent was obtained from all subjects before the initiation of the study.

Antiretroviral therapy
----------------------

As of December 2009, only HP-15 had not received HAART. In addition to two HPs that died ([Table 1](#T001){ref-type="table"}), 7 HPs (numbers 2, 8, 10, 11, 13, 14, and 16) had not been treated with HAART for the first 10 years after their diagnosis of HIV-1. Thereafter, HPs (numbers 2, 8, 10, 11, 13, 14, and 16) have been treated from April 2006, June 2007, January 2005, November 2003, February 2006, April 2009, and February 2006, respectively ([Table 1](#T001){ref-type="table"}).

###### 

Summary of 20 hemophiliac individuals infected with Korean subclade B of HIV-1 subtype B

  --------- -------------------------------------- ---------------- -------------------------------------- ------------------- --------------- -------------- --------------
  Patient   Date on diagnosis of HIV-1 infection   Prior to HAART   Plasma RNA copy (/mL) prior to HAART   Amount of KRG (g)                                  
                                                                                                                                                              
                                                   Follow-up mo     Annual decrease in CD4+ T              Monthly KRG (g)                     Before HAART   During HAART
                                                                                                                                                              
  HP 1      26-11-90                               51               28                                     22                  Not tested      1,140          No HAART
  HP 2      21-02-91                               177              27                                     10                  35,900          1,800          0
  HP 3      01-04-91                               135              49                                     15                  Not tested      2,000          No HAART
  HP 4      24-08-91                               111              70                                     11                  8,180           1,210          4,320
  HP 5      13-01-92                               28               214                                    21                  Not tested      600            No HAART
  HP 6      20-01-92                               82               72                                     0                   Not tested      0              \>5,760
  HP 7      22-01-92                               64               140                                    19                  20,000          1200           11,640
  HP 8      15-02-92                               204              1                                      74                  14,600          \>15,390       720
  HP 9      25-02-92                               171              32                                     3                   23,700          540            180
  HP 10     26-03-92                               144              28                                     5                   Not tested      780            5040
  HP 11     29-02-92                               136              72                                     1                   209,000         180            3300
  HP 12     25-02-92                               119              49                                     0                   Not tested      0              1500
  HP 13     29-02-92                               163              28                                     24                  4,000           3,900          0
  HP 14     19-02-92                               204              23                                     109                 4,146           \>21,078       1,980
  HP 15     16-09-92                               123              0                                      63                  111             7,776          No HAART
  HP 16     05-12-92                               158              22                                     9                   Not tested      1,470          \>1,000
  HP 17     26-02-93                               102              62                                     0                   3,703           0              3,120
  HP 18     02-03-93                               53               38                                     145                 Not tested      7,680          17,400
  HP 19     26-07-93                               58               84                                     0                   \>10,062        0              9,060
  HP 20     04-08-94                               51               26                                     113                 12,000          5,760          7,680
  Total     Mean±SD                                117±54           53±50                                  32±44               30,485±60,149   3,625±5,624    4,544±4,862
  --------- -------------------------------------- ---------------- -------------------------------------- ------------------- --------------- -------------- --------------

HAART, highly active antiretroviral therapy; KRG, Korean red ginseng; HP, hemophiliac patient.

Therapy with Korean red ginseng
-------------------------------

Outpatient-based clinical trial of KRG treatment in HIV-1-infected patients was initiated at the Korean National Institute of Health in late 1991. The daily dose of KRG was 5.4 g (six 300 mg capsules three times per day) for men [@B028],[@B030],[@B031]. KRG has been supplied since November 1991 although the supply of KRG was not consistent before year 2000.

CD4 T cell count and plasma RNA copy number
-------------------------------------------

At about 6-month intervals, blood was drawn from each patient and peripheral blood mononuclear cells (PBMCs) in each sample were incubated with phycoerythrin- and fluorescein isothiocyanate-conjugated antibodies against CD4 and CD8 antigens, respectively (Simultest reagent; Becton Dickinson, San Jose, CA, USA). Levels of CD4 and CD8 T cells were measured by FACScan (Becton-Dickinson) flow cytometry. Plasma HIV-1 RNA copy (/mL) were measured using the Amplicor HIV-1 Monitor kit (Roche Diagnostics, Branchburg, NJ, USA).

Amplification and sequencing of 5'LTR/gag
-----------------------------------------

One-hundred forty seven PBMCs from 20 HPs were obtained between 1991 and 2010. Proviral 5'LTR/*gag* sequences (1,125 bp) were amplified from the PBMC using nested polymerase chain reaction, as previously described [@B025],[@B027].

Statistical analysis
--------------------

The data are expressed as the means±one standard deviations (continuous variables) or as counts and percentages (categorical variables). Continuous variables were analyzed by using correlation analyses method; categorical variables were compared with the χ^2^ statistics. A *p*-value of \<0.05 were considered statistically significant.

Sequences
---------

The GenBank accession numbers are EF370244-260, EF370362-366, EF370369-372, EU047688-692, and JN613584-804.

RESULTS
=======

Significant correlation between Korean red ginseng intake and decrease in CD4 T cells
-------------------------------------------------------------------------------------

CD4 T cell counts were measured during a follow-up period of 117±54 mo prior to HAART. All patients took KRG for various durations. The amount of KRG used prior to the initiation of HAART was 3,625±5,624 g (32 g/mo) for 117±54 mo and the annual decrease in the CD4 T cell count was 53±50/μL ([Table 1](#T001){ref-type="table"}). When we focused on 13 patients who were followed up for more than 100 mo prior to HAART, there was a significant inverse correlation between amount of monthly KRG intake and annual decrease in CD4 T cells (*r*=-0.612) (*p*\<0.05).

Number of amplicons
-------------------

We obtained 436 amplicons for 5'LTR/*gag* genes from 147 PBMCs obtained over 10 yr (range, 3 to 19 yr). Of those, 92 genes (21.1%) from 53 PBMCs (36.1%) showed gross deletion in 5'LTR/*gag*.

Frequency of gross deletion in 5'LTR/gag is associated with Korean red ginseng intake
-------------------------------------------------------------------------------------

We obtained 30 amplicons at baseline (before KRG intake). Of the 30 amplicons, 3 showed gross deletion in 5'LTR/*gag* (10%) ([Fig. 1](#F001){ref-type="fig"}). During KRG intake prior to HAART, we obtained 192 amplicons. Of those, 54 showed gross deletion in 5'LTR/*gag* (28.1%, *p*\<0.05) ([Fig. 1](#F001){ref-type="fig"}).

Frequency of gross deletion in 5'LTR/gag was significantly inhibited during HAART
---------------------------------------------------------------------------------

Among the 20 patients, 16 patients received HAART for 58.5±43.0 mo (range, 4 to 124 mo; median, 66.5 mo). During the HAART period, 12 patients also received KRG. The average amount of KRG and monthly KRG were 4,544±4,862 g (range, 0 to 17,400 g) and 75 g, respectively ([Table 1](#T001){ref-type="table"}). In regard to HAART, 192 and 214 amplicons were obtained on KRG only and during KRG plus HAART, respectively. Of those, 54 (28.1%) and 35 (16.4%) showed gross deletion in 5'LTR/*gag* for the corresponding periods ([Fig. 1](#F001){ref-type="fig"}). Thus, proportion of gross deletion in 5'LTR/*gag* was significantly inhibited during HAART (*p*\<0.01).

![Changes of the proportion of gross deletion in the 5' LTR/*gag* gene (gΔ). Proportion of gΔ was significantly increased on Korean red ginseng (KRG) intake only (28.1%, 54/192) compared with that prior to KRG intake (10%, 3/30) (*p*\<0.05). The detection of gΔ was significantly inhibited during highly active antiretroviral therapy (HAART) and KRG intake compared with during KRG only (16.4%, 35/214) (*p*\<0.01).](grosbr-35-413-g001){#F001}

Nature of gross deletion and a large amplicon
---------------------------------------------

We determined sequences in 82 of 92 gross deletions in 5'LTR/*gag* from 20 HPs and found that the size of the deletions was all different in all patients although in HP-4, the same size deletions (689 bp) were repeatedly detected ([Table 2](#T002){ref-type="table"}). Interestingly, there were a case of inversion (HP-5), duplication (EF370252 in HP-8), recombination (HP-14), and insertion (HP-20) together with gross deletion in an amplicon, respectively. Among the 82 amplicons containing gross deletion in 5'LTR/*gag*, only 4 amplicons revealed gross deletion at two sites and 78 amplicons revealed it at one site. All the 82 amplicons revealed gross deletion in 5'LTR region (21 to 470 bp). Ten of the 82 amplicons did not reveal gross deletion in the *gag* region ([Table 2](#T002){ref-type="table"}). Therefore, the proportion of gross deletion in 5'LTR/*gag* was higher in 5'LTR (82/82) than that in the *gag* region (72/82).

###### 

Characteristics of gross deletions in the 5'LTR/*gag* gene

  -------------- ----------------- ------------------------- --------------------------------- --------------------------------------- ------------------------------------- ----------------------------- ----------------------------------------
  Patient code   Day of sampling   No. of bands by PCR^1)^   No. of PCR reaction with gΔ^2)^   Beginning nt. relative to HIV-1 NL4-3   Size of deletion in 5' LTR (bp)^3)^   Size of deletion in gΔ (bp)   A representative GenBank accession no.
                                                                                                                                                                                                           
  HP-2           21-10-01          1                         1                                 330                                     459                                   463                           JN613586
                 13-09-07          1                         1                                 701                                     84                                    0                             
                 12-06-08          1                         1                                 607                                     262                                   144                           JN613587
  HP-3           29-08-02          2                         1                                 440                                     349                                   407                           JN613584
  HP-4           11-10-02          1                         4                                 484                                     306                                   383                           JN613588
                 27-02-03          1                         3                                 484                                     306                                   383                           JN613589
                 04-01-08          1                         2                                 484                                     306                                   383                           JN613591
                 30-06-08          1                         2                                 484                                     306                                   383                           JN613593
                 22-12-08          1                         1                                 657                                     132                                   261                           JN613595
  HP-5           28-12-94          2                         3                                 579                                     212                                   437                           6082s
                 27-02-95          1                         1                                 627                                     162                                   373                           6083s
  HP-6           17-11-02          1                         1                                 443                                     Inversion                                                           JN613661
  HP-7           20-10-96          1                         1                                 432                                     358                                   531                           JN613596
                                   2                         1                                 483                                     288                                   0                             JN613597
                 27-02-97          2                         1                                 350                                     435                                   0                             JN613598
                 07-01-03          2                         1                                 603                                     186                                   126                           3568s1
  HP-8           19-04-95          1                         1                                 657                                     133                                   322                           EF370245
                 15-02-01          1                         1                                 632                                     158                                   228                           EF370250
                 12-12-02          1                         3                                 632                                     158                                   478                           EF370252
                 03-05-04          1                         1                                 110                                     159                                   0                             EF370256
                 06-02-06          1                         1                                 163                                     8 Plus 17                             0                             EF370259
                 27-09-07          1                         3                                 623                                                                                                         JN613599
                 26-04-10          1                         1                                 727                                     62                                    457                           9198s
  HP-9           13-12-02          2                         1                                 Different                               ND                                                                  
                                   2                         1                                 625                                     164                                   587                           JN613600
                                   2                         1                                 385                                     406                                   245                           JN613601
                                   2                         1                                 328                                     462                                   110                           
                 20-11-03          1                         1                                 412                                     375                                   36                            1651s
                 07-09-06          2                         1                                 713                                     77                                    480                           JN613602
                                   3                         1                                 722                                     68                                    590                           JN613603
                                                                                               342                                     447                                   334                           JN613604
                 19-12-07          2                         1                                 ND                                                                                                          JN613605
                                   2                         2                                 484                                     306                                   5                             JN613606
  HP-10          30-08-02          1                         1                                 637                                     153                                   467                           JN613608
                                   2                         1                                 ND                                      ND                                                                  
                                   2                         1                                 453                                     337                                   271                           JN613607
                 13-09-07          1                         1                                 639                                     151                                   19                            JN613609
  HP-11          30-10-02          2                         1                                 320                                     470                                   153                           EF370364
                                   1                         1                                 304                                     197                                   0                             EF370366
                 09-11-03          1                         1                                 420                                     370                                   177                           6021
                                   2                         2                                 613                                     178                                   555                           JN613610
  HP-12          25-10-02          1                         1                                 390                                     343                                   0                             JN613612
                                   1                         1                                 602                                     21                                    0                             JN613711
                 09-04-07          1                         1                                 677                                     113                                   321                           JN613613
                                   1                         1                                 ND                                                                                                          JN613614
                 01-04-09          1                         1                                 635                                     118                                   0                             6339
                 24-08-09          1                         1                                 736                                     43                                    0                             
                 14-05-10          1                         1                                 667                                     123                                   310                           9197s
  HP-14          11-12-96          2                         3                                 ND                                                                                                          
                 08-01-03          2                         2                                 635                                     Rec                                                                 3564s
                 23-05-07          1                         1                                 ND                                                                                                          
                 15-10-09          1                         1                                 371                                     420                                   347                           
                 27-05-10          1                         1                                 667                                     123                                   552                           JN613621
  HP-13          10-03-99          1                         1                                 591                                     199                                   605                           JN613615
                 11-28-02          2                         1                                 424                                     366                                   108                           JN613616
                 03-04-03          2                         1                                 627                                     163                                   372                           JN613617
                                   2                         1                                 644                                     146                                   533                           JN613618
                 19-04-07          1                         3                                 354                                     436                                   119                           JN613619
                                                                                                                                                                             89+                           
  HP-15          08-03-03          2                         1                                 ND                                                                                                          
  HP-16          12-09-02          1                         1                                 579                                     211                                   362                           EU047689
  HP-17          03-11-02          2                         1                                                                                                                                             JN613624
                 20-02-03          2                         2                                 426                                     364                                   21                            JN613622
                 10-08-04          1                         1                                 671                                     119                                   65                            JN613759
                 16-01-07          1                         1                                                                         About 200                             ND                            ND
  HP-18          12-04-95          2                         2                                 ND                                                                                                          
                 27-04-06          1                         1                                 659                                     131                                   505                           JN613625
  HP-19          07-11-07          1                         1                                 655                                     135                                   593                           JN613627
  HP-20          27-02-03          2                         1                                 567                                     223                                   493                           JN613628
                 08-07-03          1                         2                                 535                                     255                                   587                           JN613629
                 05-06-08          1                         1                                 727 ^e^                                 63                                    210                           JN613630
                 16-03-10          1                         1                                 669                                     121                                   334                           JN613631
  -------------- ----------------- ------------------------- --------------------------------- --------------------------------------- ------------------------------------- ----------------------------- ----------------------------------------

PCR, polymerase chain reaction; gΔ, *gag* gene; HP, hemophiliac patient; ND, not determined; Rec, recombination.

^1)^1 and 2 denote single short band only and wild type together with short band, respectively.

^2)^No. of PCR product with gΔ out of 4 PCR reactions.

^3)^Base pair.

High frequency of nonfunctional genes by G-to-A hypermutations
--------------------------------------------------------------

We determined sequences in 27 amplicons prior to KRG. There was no premature stop codon among the 27 amplicons. We determined sequences for 147 amplicons on KRG only and for 179 amplicons on KRG plus HAART. Maximum number of premature stop codon was 3 in an amplicon. Compared with that prior to KRG therapy (0/27), the amplicons during KRG plus HAART (at 36 codons) revealed significantly higher frequency of stop codons (*p*\<0.05). There was also a significant difference between KRG only (at 15 codons) and KRG plus HAART (*p*\<0.05). However, when we strictly exclude the amplicons containing gross deletion in the *gag* gene, the number of amplicons prior to KRG, on KRG only, and on KRG plus HAART were 18, 107, and 147, respectively ([Table 3](#T003){ref-type="table"}).

###### 

Frequency of genetic defects in Gag protein

  ----------------------------------------------------------------------------- --------------------- ---------------- ------------------- ---------------
  Patient                                                                       Prior to KRG intake   On KRG only      On KRG plus HAART   *p*-value^1)^
                                                                                                                                           
  No. of PCR amplicons                                                          18                    107              147                 
  No. of premature stop codon                                                   0                     15               36                  ˂ 0.05
  No. of I at initiation codon                                                  0                     6                9                   
  No. of total codons (%)                                                       0^2)^                 521 (19.6)^2)^   45 (30.6)           ˂ 0.01
  No. of PCR amplicon with genetic defects^3)^                                  0                     8 (7.5)          20 (13.6)           
  No. of PCR amplicon with G-to-A hypermutations only without genetic defects   0                     3                6                   
  No. of total amplicons with G-to-A hypermutations (%)                         0                     11 (10.3)        26 (17.7)           
  ----------------------------------------------------------------------------- --------------------- ---------------- ------------------- ---------------

KRG, Korean red ginseng; HAART, highly active antiretroviral therapy; PCR, polymerase chain reaction.

^1)^*p* -value between prior to KRG intake and on KRG plus HAART.

^2)^*p*˂0.05 between prior to KRG intake and on KRG only.

^3)^Genetic defects denote premature stop codon and isoleucine at the initiation codon.

In addition, isoleucine at the initiation codon of Gag protein was detected in six and nine amplicons in KRG only and KRG plus HAART, respectively ([Table 3](#T003){ref-type="table"}). It was not detected in 18 amplicons before KRG intake. Among the six and nine isoleucines, 5 and 8 were detected together with premature stop codon, respectively. These genetic defects resulted from G-to-A hypermutations (by Hypermut 2.0; Los Alamos National Laboratory, Los Alamos, NM, USA). However, 3 on KRG only and 6 amplicons on KRG plus HAART did not showed genetic defects although they belong to G-to-A hypermutations ([Table 3](#T003){ref-type="table"}). Differing from the frequency of gross deletion, frequency of G-to-A hypermutations seems higher on KRG plus HAART than KRG only.

Proportion of overall genetic defects
-------------------------------------

Adding the gross deletions to premature stop codon or isoleucine at initiation codon based on amplicon, the proportions of genetic defects were 10% (3/30) before KRG intake, 33.5% (63/188) on KRG only before HAART and 25.7% (55/214) on KRG plus HAART, respectively. The latter two groups showed significant high proportion of genetic defects compared with data before KRG intake (*p*\< 0.001 for both) ([Fig. 2](#F002){ref-type="fig"}).

![Changes of the proportion of all genetic defects including gross deletion in the 5'LTR/*gag* gene (gΔ). Proportion of genetic defects significantly increased on Korean red ginseng (KRG) intake only (63/188) and KRG plus highly active antiretroviral therapy (HAART, 55/214) compared with that prior to KRG intake (3/30) (respectively, *p*\<0.001) although there was no significant difference between KRG intake only and KRG plus HAART. However, G-to-A hypermutations were higher on KRG plus HAART than KRG only.](grosbr-35-413-g002){#F002}

Novel insertion, inversion, or duplication in 5'LTR
---------------------------------------------------

Novel insertions of 7 bp and 8 bp in 5'LTR were detected in an amplicon in HP-8 (GenBank numbers, EF370257 and EF370258, respectively). Deletion of 9 bp from position 108 and inversion of 609 bp and deletion of 5 bp was observed in seq 3476 in HP-6. A gross deletion and duplication of 105 bp in HP-8 was also observed (GenBank number, EF370252). In HP-13, unusual recombination of terminal 75bp was observed (seq3564s). In HP-20, seq4809 revealed deletion of 273 bp from 727 to 998 and it was replaced with insertion of env gene (367 bp from 8530 to 8896) ([Table 2](#T002){ref-type="table"}).

DISCUSSION
==========

In this study, we found that frequency of gross deletion in 5'LTR/*gag* is also associated with KRG intake and that the frequency of gross deletion in 5'LTR/*gag* is significantly decreased on KRG plus HAART compared with that prior to HAART. These findings are the same as shown in the frequency of gΔ*nef* in the previous study [@B026]. This observation may reflect a limit dilution because deleted genes might comprise a minor portion compared with to intact genes in vivo, thus decreasing the chance of detection of gross deletion in 5'LTR/*gag* gene. However, we found a few different findings compared with gΔ*nef* in the same study population. First, there was no difference in the frequency of 5'LTR/*gag* on KRG only between 20 HPs (28.1%) and 3 HPs (-21, 22, and 23) (24.6%; 15/61) who were infected with non-KSB in other countries [@B012]. In contrast, our previous report showed that the frequency of gΔ*nef* in 20 HPs (20.6%) was 10-fold higher than that (2/100) in 3 HPs (-21, 22, and 23) infected with non-KSB. Taken together, our data suggest that 5'LTR/*gag* region might be more sensitive to KRG intake than in the Δ*nef*. Second, we obtained higher frequency of nonfunctional gene (premature stop codon and I instead of M as initiation codon in Gag protein) (10.3%, 11/107) on KRG intake only. In addition to nonfunctional *gag* gene, there were also frequent G-to-A hypermutations in the *vif* genes (unpublished data). These frequencies in 5'LTR/*gag* and *vif* genes were significantly higher compared to 0.96% (5/522) [@B026] in the Δ*nef* in the same patients and 0% (0/277) in other patients (*p*\<0.001) [@B028].

There are many reports on gΔ*nef* reported in many studies. However, there is no report on gross deletion in 5'LTR/*gag* gene together with gΔ*nef*. In detail, Huang *et al*. [@B032] reported genetic defects in the 5'LTR and *gag* genes of eight long-term survivors. In their work, full viral sequences were obtained. G-to-A hypermutations were seen in only one patient in *gag* gene and 5'LTR. However, there was no gross deletion in the 5'LTR and Δ*nef*. Recently, Calugi *et al*. [@B033] identified gross deletions in the *env* gene (next to the Δ*nef*). Blankson and Siliciano [@B034] and Blankson [@B035] did not detect any gross deletions in full-length sequences of HIV-1 even in elite suppressors, with viral loads of plasma RNA less than 50 copies/mL.

Despite many limitations, this study showed that the frequency of gross deletion in 5'LTR/*gag* is associated with KRG intake. Although further study is needed to determine the source of high frequency of genetic defects in HIV-1 in hemophiliacs, these data provide a new perspective on HIV-1 pathogenesis.
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